EUVIMEDEUVIMED entdecken
Crossref

Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran

Negin Bashari, Majid Safaei Lari, Ali Darvishi, Rajabali Daroudi

Expert Review of Pharmacoeconomics & Outcomes Research · 2024

DOI: 10.1080/14737167.2023.2263164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Negin Bashari und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Health Insurance Research, Tehran, Iran. Hauptthemen laut MEDLINE: Melanoma, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Tehran University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Immunotherapy drugs like Pembrolizumab have shown significant improvements in treatment outcomes of advanced melanoma. This study aimed to evaluate the cost-utility of Pembrolizumab compared to other immunotherapy and chemotherapy drugs in the first-line treatment of advanced melanoma in Iran. METHODS: A partitioned-survival model, based on data from a recent randomized phase 3 study (KEYNOTE-006) and recent meta-analysis, was used to divide Overall survival (OS) time into Progression-free survival (PFS) and post-progression survival for Pembrolizumab, Nivolumab, Ipilimumab, Dacarbazine, Temozolomide, Carboplatin, and Paclitaxel combination. Quality Life Years (QALY) and Incremental Cost-Effectiveness Ratio (ICER) were considered as the final outcome. RESULTS: The ICER of Ipilimumab, Nivolumab, Nivolumab & Ipilimumab, and Pembrolizumab compared to Temozolomide was calculated as $40,365.53, $19,591.13, $24,578, and $47,324.2 per QALY, respectively. Scenario analysis demonstrated if the price of one vial of Nivolumab 100 is $90.51, each vial of Pembrolizumab is $119.20, and each vial of Ipilimumab is $101.54, they will be cost-effective in Iran. CONCLUSION: None of the immunotherapy drugs studied were found to be cost-effective when considering the cost-effectiveness threshold of $3,532. Therefore, a cost reduction of more than 90% in the prices of immunotherapy drugs would be necessary for them to be considered cost-effective in Iran.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntibodies, Monoclonal, HumanizedHumansIpilimumabNivolumabCost-Benefit AnalysisTemozolomideIranImmunotherapyQuality-Adjusted Life YearsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Pembrolizumabadvanced melanomachemotherapycost-utilityeconomic evaluation

Substanzen

pembrolizumabIpilimumabNivolumabTemozolomideAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • National Center for Health Insurance Research, Tehran, Iran.
  • Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Förderung

  • Tehran University of Medical Sciences

Zitieren

APA

Bashari, N., Safaei Lari, M., Darvishi, A., & Daroudi, R. (2024). Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2263164

Vancouver

Bashari N, Safaei Lari M, Darvishi A, Daroudi R. Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2023.2263164

BibTeX
@article{Bashari2024,
  author = {Bashari, Negin and Safaei Lari, Majid and Darvishi, Ali and Daroudi, Rajabali},
  title = {Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2024},
  doi = {10.1080/14737167.2023.2263164}
}
Kostenlos starten →